News Releases

Two Penn Medicine researchers have developed a unifying definition of “cytokine storm” to provide physicians with a framework to assess and treat severely-ill patients whose immune systems have gone rogue.

In a new study published online today in Nature Cancer, Penn Medicine researchers found that combining chimeric antigen receptor (CAR) T cell therapy with a PAK4 inhibitor drug allowed the engineered cells to punch their way through and attack the tumor, leading to significantly enhanced survival in mice.

Since COVID-19 acutely affects the respiratory system, airway management is a significant concern among patients.

A new University of Pennsylvania (Penn) research collaboration with Regeneron Pharmaceuticals, Inc. will investigate whether Regeneron’s casirivimab and imdevimab investigational antibody cocktail can prevent COVID-19 infection when delivered intranasally via Adeno-Associated Virus (AAV) vectors.

Penn Medicine’s E. Michael Ostap, PhD, and Qi Long, PhD, have been named 2020 Fellows of the American Association for the Advancement of Science (AAAS) for their distinguished efforts toward advancing science and maintaining the highest standards of professional ethics and scientific integrity.

Ingo Helbig, MD, a pediatric neurologist in the Division of Neurology at Children's Hospital of Philadelphia, director of the genomic and data science core of the CHOP Epilepsy Neurogenetics Initiative, and Assistant Professor of Neurology and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, has been named a recipient of a 2019 Hartwell Individual Biomedical Research Award.

Marginalized groups of people value professionalism more — and are more likely to leave a job at an institution due to issues of professionalism — compared to their white, male counterparts, according to a Penn Medicine study of staff, faculty, and students who were affiliated with a large, academic health system in 2015 and 2017.